Please provide your email address to receive an email when new articles are posted on . Dapagliflozin was safe and effective at 1 year among older patients with aortic stenosis and HF who underwent ...
Preliminary results of the largest, longest, and broadest cardiovascular outcomes trial (CVOT) to date with a type 2 diabetes drug reveal that the sodium-glucose cotransporter type 2 (SGLT2) inhibitor ...
Treatment with dapagliflozin reduced the risk of death or worsening heart failure by 28% compared with standard of care. Dapagliflozin reduced the risk of death or worsening heart failure (HF) in ...
Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...
Dapagliflozin safe and effective in elderly patients with heart failure undergoing valve replacement
Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...
Dapagliflozin reduced left ventricular mass index early into treatment in patients with nondialysis-dependent CKD, regardless of disease etiology and cardiovascular history. Dapagliflozin reduces left ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback